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Recent reports have associated NCF2, encoding a core component of the multi-protein NADPH oxidase
(NADPHO), with systemic lupus erythematosus (SLE) susceptibility in individuals of European ancestry.
To identify ethnicity-specific and -robust variants within NCF2, we assessed 145 SNPs in and around the
NCF2 gene in 5325 cases and 21 866 controls of European-American (EA), African-American (AA), Hispanic
(HS)andKorean (KR)ancestry.Subsequent imputation,conditional,haplotypeandbioinformaticanalyses iden-
tified seven potentially functional SLE-predisposing variants. Association with non-synonymous rs17849502,
previously reported in EA, was detected in EA, HS and AA (PEA 5 1.01 3 10
254, PHS 5 3.68 3 10
210, PAA 5
0.03); synonymous rs17849501 was similarly significant. These SNPs were monomorphic in KR. Novel associa-
tions were detected with coding variants at rs35937854 in AA (PAA5 1.49 3 10
29), and rs13306575 in HS and KR
(PHS 5 7.04 3 10
27,PKR 5 3.30 3 10
23). InKR,a3-SNPhaplotypewassignificantlyassociated(P 5 4.20 3 1027),
implying that SLE predisposing variants were tagged. Significant SNP–SNP interaction (P 5 0.02) was detected
between rs13306575 and rs17849502 in HS, and a dramatically increased risk (OR 5 6.55) with a risk allele at each
locus. Molecular modeling predicts that these non-synonymous mutations could disrupt NADPHO complex
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assembly. The risk allele of rs17849501, located in a conserved transcriptional regulatory region, increased re-
porter gene activity, suggesting in vivo enhancer function. Our results not only establish allelic heterogeneity
withinNCF2 associated with SLE, but also emphasize the utility of multi-ethnic cohorts to identify predisposing
variants explaining additional phenotypic variance (‘missing heritability’) of complex diseases like SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE or lupus) is a clinically het-
erogeneous, systemic autoimmune disease affecting 2 million
people in the USA, about 90% of whom are women (1). The pro-
found morbidity and mortality of SLE stem from chronic inflam-
mation and multiple organ damage. Because lupus patients have
weakened immune systems from standard immunosuppressant
treatment (2–7) and immune dysregulation, infection is a leading
cause of morbidity and mortality, accounting for .25% of
SLE-related deaths (2,3,8–9).
Both innate immunity and global regulation of the immune
system depend on generation of reactive oxygen species (ROS)
such as superoxide (O2†2) and hydrogen peroxide (H2O2).
Pathogen clearance by phagocytosis depends on ROS production
by phagocytes, i.e. neutrophils, monocytes and macrophages, and
deficient ROS generation may give rise to infection susceptibility.
Conversely, overproduction of ROS may lead to oxidative stress
that stimulates autoimmune responses (10–12). Given the deli-
cate ROS balance required for proper immune function, it is not
surprising that mutations in ROS regulators may contribute to
both immune dysfunction and susceptibility to chronic infections
(13).At the core of the ROS productionmachinery isnicotinamide
adenine dinucleotide phosphate oxidase (NADPHO), a multi-
subunit membrane protein that catalyzes oxidation of NADPH.
NADPHO consists of five core phagocytic oxidase (‘phox’) pro-
teins, p22phox/cytochrome b-245 alpha (CYBA), gp91phox/Nox2/
cytochrome b-245 beta (CYBB), p47phox (NCF1), p67phox
(NCF2) and p40phox (NCF4). The NADPHO complex is activated
by one or more soluble GTPases in each phagocytic class (Supple-
mentary Material, Fig. S1). The dominant NADPHO-activating
GTPase is Rac1 in monocytes and Rac2 in neutrophils. Both
GTPases appear to play a role in macrophages (14). A specific
guanine nucleotide exchange factor (GEF), such as Vav1, is
required to activate the GTPase (15).
Recently NCF2, which encodes p67phox, was identified as an
SLE susceptibility gene (16–18). An intronic SNP (rs10911363)
was implicated in SLE pathogenicity in individuals with European
ancestry (16,17). In Chinese individuals this SNP was not asso-
ciated with SLE, but it was associated with arthritis and anti-
nuclear antibody production (19). Fine-mapping by Jacob et al.
(18) suggested that missense variant rs17849502 (H389Q) under-
lies NCF2-SLE association in European-derived populations.
However, this could not be confirmed in other ethnic populations
because of low minor allele frequency (MAF) and small sample
sizes. Such disparate and inconclusive results are not uncommon
for SLE, given the strong influence of ancestry on SLE predispos-
ition and progression. SLE pathology is influenced by numerous
molecular pathways and ethnicity-specific genetic associations
(20,21), which suggests that distinct sets of genetic interactions
modulate SLE risk in different populations. Also, prevalence and
severity of SLE are markedly higher in individuals with African,
Asian or Hispanic ancestries compared with those with European
ancestry (22–24). Thus, analyzing multiple ethnic populations is
crucial for understanding the disease mechanisms of SLE (25).
To thoroughly investigate SLE-NCF2 association in ethnical-
ly diverse populations, and to identify both ethnicity-specific and
-robust causal variants, we analyzed a large multi-ethnic cohort.
The objectives of this study were to (i) perform comprehensive
analysis using dense fine-mapping, (ii) identify robust, inde-
pendent SLE-predisposing variants and (iii) predict and validate
the molecular effects of SLE risk alleles through bioinformatics,
molecular modeling, and in vitro assays.
RESULTS
Study populations and genotypic data
Our large-scale association study included 12 256 participants
from four ethnically diverse populations including European-
American (EA), African-American (AA), Hispanic (HS) and
Korean (KR) individuals (Supplementary Material, Table S1).
All SLE patients satisfied American College of Rheumatology
classification for SLE (26,27). Controls had no history of auto-
immune disease and were considered healthy.
Our study design with workflow is shown in Figure 1. Indivi-
duals were genotyped on the Illumina ImmunoChip array (28) as
a part of separate projects led by collaborators. Additional
healthy controls were obtained from dbGaP (29). Subjects
were excluded from analysis for low call rate (,98%), cryptic
relatedness to another study participant (identity by descent
.25%), or being outliers identified by principal component ana-
lysis (PCA) (Supplementary Material, Fig. S2). After quality
control (QC) there were 4804 SLE cases and 7452 healthy con-
trols: EA (1476 cases, 2693 controls), HS (829 cases, 1181 con-
trols), AA (686 cases, 371 controls) and KR (1813 cases, 3207
controls) (Supplementary Material, Table S1).
A total of 145 SNPs in and around theNCF2 region (Build 37;
Chr1: 183,523,470-183,573,858) were examined. SNPs were
removed if they were out of Hardy–Weinberg equilibrium
(PHWE , 0.001 in controls), had .10% missing genotype
calls, clustered too poorly to separate genotype calls, or had
MAF ,0.5%. After QC, 118 SNPs were analyzed, including
74 SNPs in EA, 83 in HS, 94 in AA and 75 in KR. Case–
control association studies were analyzed by x2 test, and odds
ratios (ORs) and 95% confidence intervals (95% CIs) were cal-
culated for each population using PLINK (30).
Initial case–control association analysis
The initial analysis showed significant association (P , 0.05)
with SLE for 26 SNPs in EA, 5 in HS, 6 in AA, and 41 in KR (Sup-
plementary Material, Table S2). The strongest association was at
rs17849501 (A202A) in EA and HS [PEA ¼ 5.23 × 10233, OR
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(95% CI) ¼ 2.73 (2.31–3.24); PHS ¼ 2.97 × 1026, OR (95%
CI) ¼ 1.94 (1.46–2.56)]. Our results confirmed strong SLE as-
sociation in EA and HS with the previously identified risk
allele at rs17849502 (H389Q) (18) [PEA ¼ 1.93 × 10228, OR
(95% CI) ¼ 2.48 (2.10–2.92); PHS ¼ 7.01 × 1027, OR (95%
CI) ¼ 2.03 (1.53–2.69)]. Both of these SNPs were monomorph-
ic in KR, and both failed to pass QC in AA due to low MAF
(0.006 in controls). Novel association at non-synonymous SNP
rs35937854 (V297A) was the strongest association in AA
[PAA ¼ 7.15 × 1024, OR (95% CI) ¼ 2.20 (1.38–3.51)], but
was monomorphic in other populations. In KR, the strongest as-
sociation was at intronic SNP rs10911357 [PKR ¼ 7.75 × 1024,
OR (95% CI) ¼ 1.16 (1.06–1.26)].
Imputation-based association analysis, adjusted for
multiple testing and ancestry correction
To increase the statistical power of our analysis, we performed a
comprehensive ethnicity-specific imputation-based analysis.
We incorporated an additional 11 968 EA and 1603 AA
healthy out-of-study controls from dbGaP, as well as 521 HS
SLE cases and 843 healthy HS controls obtained through collab-
oration (Supplementary Material, Table S1; Fig. 1). We also
increased fine-mapping density by imputing additional NCF2
SNPs from 1000 Genomes Project data using MACH-ADMIX
(31). QC criteria described earlier were applied to these
samples and SNPs. Additionally, SNPs had to pass imputation
quality metric (Rsq . 0.7).
After imputation and QC, 250 SNPs were available for ana-
lysis (Supplementary Material, Table S3). We adjusted the sig-
nificance threshold of a ¼ 0.05 to account for multiple testing.
Spectral decomposition of the pair-wise LD matrices (32,33)
was used to account for inter-SNP correlation due to linkage dis-
equilibrium (LD), allowing us to determine the effective number
of independent SNPs separately for each population. Based on
this calculation, we determined a population-specific adjusted
experiment-wise significance threshold at the 5% level: EA
(P ≤ 1.33 × 1023, 152 total SNPs and 6 independent SNPs),
HS (P ≤ 1.70 × 1023, 134, 11), AA (P ≤ 4.95 × 1024, 214,
5) and KR (P ≤ 2.00 × 1023, 164, 5).
Imputation-based analysis supported our initial results.
rs17849502 was the most strongly associated SNP in EA
[PEA ¼ 1.01 × 10254, OR (95% CI) ¼ 2.57 (2.28–2.91)] and
was also highly significant in HS [PHS ¼ 3.68 × 10210, OR
(95% CI) ¼ 2.02 (1.62–2.53)]. In both populations,
rs17849501 was similarly associated [PEA ¼ 4.45 × 10254,
OR (95% CI) ¼ 2.56 (2.26–2.90); PHS ¼ 3.34 × 10210, OR
(95% CI) ¼ 2.02 (1.61–2.52)], and was in strong LD with
rs17849502 (Supplementary Material, Fig. S3). Since the
MAF in AA was too low for reliable imputation (MAF
rs17849502 ¼ 0.0066, MAF rs17849501 ¼ 0.0056 in controls), we
genotyped rs17849502 and rs17849501 in a subset of 603 AA
cases and 384 AA controls using a TaqMan assay. Despite the
reduced sample size and low MAF, both SNPs were significantly
associated with SLE [Prs17849502 ¼ 0.02, OR (95% CI) ¼ 2.76
(1.14–6.68); Prs17849501 ¼ 0.007, OR (95% CI) ¼ 3.88 (1.36–
11.10)]. Consistent with our initial results, the strongest associ-
ation in AA was at rs35937854 [V297A; PAA ¼ 1.49 × 1029,
OR (95% CI) ¼ 2.34 (1.76–3.11)]. In KR, the strongest SLE as-
sociation was an imputed intronic SNP, rs10911359 [PKR ¼
6.82 × 1024, OR (95% CI) ¼ 1.16 (1.06–1.26)].
Robustness of our analyses was assessed using covariate
adjusted logistic regression implemented in PLINK (see
Methods and Materials). Using ADMIXTURE (34) software,
we detected three ancestral components as optimal for describ-
ing AA, KR and EA, whereas four ancestral components best
described HS. Individual ancestry proportions were used as cov-
ariates to correct for potential effects of population structure on
association (Supplementary Material, Table S3). Results were
confirmed by principal component analysis (PCA, implemented
in GCTA) (35) using the first three principal components covari-
ates (Supplementary Material, Table S3). For both covariate
adjusted result sets the magnitude of significance was consistent
with the unadjusted results, with the exception of rs17849502/
rs17849501 in EA, and rs13306575 in HS, where ancestry
might have a small impact on the strength of association (Supple-
mentary Material, Table S3). Both associations remain signifi-
cant following ancestry adjustment.
Figure 1. Workflow and study design of the present study.
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Identification of independent variants in four ethnicities
We performed conditional analysis to detect independently asso-
ciated variants in each population (Supplementary Material,
Table S4). Population-specific haplotypes were constructed
using independent SNPs identified through conditional analysis.
Interactions between independently associated SNPs in each
population were also assessed using additional methods
(described below).
SLE association of the NCF2 region in EA was explained by
rs17849502 (H389Q) and rs17849501 (A202A). Conditioning
on either SNP explained SLE significance in EA (using threshold
P. 1.33 × 1023) (Supplementary Material, Fig. S4). Because
of the strong LD between these SNPs (D′ ¼ 1.0, r2 ¼ 0.99,
9743 bp apart), we could not dissect separate contributions of
each SNP (Supplementary Material, Fig. S3) and considered
these SNPs together.
In HS both rs17849502 and rs17849501 were also highly sig-
nificant [PHS ¼ 7.04 × 1027, OR (95% CI) ¼ 1.56 (1.31–
1.86)] and in high LD (D′ ¼ 1.0, r2 ¼ 0.98). Additionally, non-
synonymous variant rs13306575 (R395W) was independently
associated with SLE (Table 1) [PHS ¼ 7.04 × 1027, OR (95%
CI) ¼ 1.56 (1.31–1.86)]. rs13306575 was also significant in
KR [PKR ¼ 3.30 × 1023, OR (95% CI) ¼ 1.43 (1.13–1.83)]
in the same direction (Fisher’s combined P-value for
PHS&KR ¼ 4.85 × 1028). The omnibus haplotype association
was highly significant (Phap ¼ 4.75 × 10214) (Supplementary
Material, Table S5). Conditioning on haplotypes with a risk
allele at only one SNP did not explain the omnibus haplotype sig-
nificance (Pcond:GT ¼ 2.33 × 1029; Pcond:AG ¼ 5.60 × 10210),
but conditioning on the protective haplotype ‘GG’ accounted
for the entire omnibus haplotype association (Pcond:GG ¼ 0.09)
(Supplementary Material, Fig. S5). Haplotype analysis includ-
ing rs17849501/rs13306575 produced similar results (data
not shown). Thus in HS, SLE association is explained by
rs13306575 and rs17849502/rs17849501, the latter acting as
an indistinguishable effect.
We observed a significant SNP–SNP interaction between in-
dependent, missense SNPs rs17849502 and rs13306575 using a
logistic regression model implemented in R (PC-corrected P ¼
0.024, ancestry-correctedP ¼ 0.025). This result was confirmed
by parametric FITF (36), epistasis test (P ¼ 0.018), PLINK two-
locus test (P ¼ 0.02) and GAIA (P ¼ 0.038). We confirmed this
interaction (sign test P ¼ 1 × 1023) using non-parametric gen-
eralized multifactor-dimensionality reduction (GMDR). In
GMDR, the best-fitted interaction model was between these two
SNPs, with a cross-validation consistency of 9 out of 10, and a
testing accuracy of 55%. We then compared cases and controls
with no risk alleles to individuals with a risk allele at both SNPs
and found a dramatic increase in SLE risk [OR (95% CI) ¼ 6.55
(2.84–15.11)]. Possessing a risk allele at only one SNP showed
a marginal increase in SLE risk [risk at rs13306575, OR¼ 1.52
(1.25–1.85); risk at rs17849502, OR ¼ 1.78 (1.38–2.28)].
In AA, non-synonymous rs35937854 (V297A) and intronic
rs34680162 were independently associated with SLE (Table 1).
Conditional analysis on overall haplotype association (Phap¼
2.93 × 10211) confirmed that neither SNP fully explained associ-
ation (Pcond: rs35937854 ¼ 1.15 × 1024; Pcond: rs34680162¼ 2.20 ×
1029) (Supplementary Material, Fig. S6 and Table S5). No
observed haplotypes contained risk alleles at both SNPs. T
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Conditioning on haplotypes including risk alleles at only one SNP
did not explain the omnibus haplotype significance (Pcond:AC ¼
2.20 × 1029; Pcond:GA ¼ 1.15 × 1024), but conditioning on the
protective haplotype ‘AA’ explained haplotypic association
(P ¼ 0.28). No SNP–SNP interactions were observed.
In KR, we identified three novel independently associated
NCF2 SNPs: non-synonymous variant rs13306575, and intronic
variants rs10911359 and rs34423782 (Table 1) in low LD with
one another (Supplementary Material, Fig. S3). No SNP fully
explained the overall omnibus haplotype association (Phap¼
4.20 × 1027; Pcond: rs13306575 ¼ 9.50 × 1026; Pcond: rs10911359 ¼
3.14 × 1024; Pcond: rs34423782 ¼ 2.72 × 1025). Likewise, condi-
tioning on single haplotypes did not explain overall haplotype sig-
nificance (Pcond: GTT ¼ 2.72 × 1025;P cond: GCC ¼ 3.14 × 1024;
P cond:ATC ¼ 1.26 × 1025; P cond:GTC ¼ 3.17 × 1025) (Supple-
mentary Material, Fig. S7). No haplotypes containing more than
one risk allele were observed, and no SNP–SNP interactions
were observed. Both rs10911359 and rs34423782 lie within
active chromatin regions in GM12878 cells (a lymphoblastoid
cell line); both risk alleles disrupt CpG dinucleotides within
tracks of methylated sequence (ENCODE/MeDIP track).
We assessed the heterogeneity of OR across populations for
independently associated SNPs that passed QC in at least two
populations. Control allele frequencies were consistent with
HapMap frequencies for each population. We found that for all
but one SNP the ORs were homogeneous across populations.
For rs10911359, which was only significant in Koreans, the
ORs were heterogeneous (P ¼ 0.0056).
In silico functional analysis
Together, the conditional analyses identified seven associated
SNPs with six independent effects (counting rs17849501 and
rs17849502 together) in the NCF2 region; three of these were
non-synonymous variants. Because each non-synonymous mu-
tation was monomorphic in at least one population, a single
amino acid change (e.g. H389Q) (18) cannot explain the NCF2
association in all populations. To better understand how
genetic variation in these populations influences SLE suscepti-
bility, independently associated variants, coding and non-
coding, were scanned in silico to assess their possible functional
effects on NCF2 or directly adjacent genes.
We focused on probes targeting NCF2 and its adjacent genes,
SMG7 and ARPC5, using genotype data from HapMap and the
1000 Genomes Project and expression data from GeneVar
(37,38) for expression quantitative trait locus (eQTL) analysis.
A linear model was fitted for population-specific eQTL expres-
sion data versus NCF2 SNP genotypes for 153 HapMap
samples using PLINK. Five SNPs (rs13306575, rs17849502,
rs34680162, rs17849501, rs10911359; Supplementary Mater-
ial, Fig. S8, Table S6) were significantly associated with
cis-eQTLs at the SMG7 probe (GI_42476073-A). These results
were also assessed using data from the mRNA browser
(39,40). Since none of these SNPs were available in the
mRNA browser, we used tagged SNPs that were in LD (r2 or
D′ ≥ 0.8) with our SNPs (Supplementary Material, Table S6)
to assess associations with mRNA transcript abundance.
Four tagged SNPs, rs1044879 (D′ ¼ 1, r2 ¼ 1 with
rs17849501 and rs17849502 in CEU, PmRNA ¼ 1.4 × 10217),
rs796860 (D′ ¼ 1, r2 ¼ 0.05 with rs10911359 on YRI,
PmRNA ¼ 5.0 × 1024), rs2296164 (D′ ¼ 1, r2 ¼ 1 with
rs10911359 in CEU and CHB + JPT, PmRNA ¼ 2.6 × 10210)
and rs2274064 (D′ ¼ 1, r2 ¼ 0.02 with rs10911359 and
rs34423782 in CHB and JPT, PmRNA ¼ 6.2 × 10210) were sig-
nificantly associated with transcript abundance of SMG7, but
not NCF2 or ARPC5. Of note, although two tag-SNP pairs
(rs796860- rs10911359 and rs2274064- rs34423782) had low
correlation (r2), their minor alleles were on the same haplotype
(D′ ¼ 1). rs10911359 is in perfect correlation with rs2296164,
leaving only rs34423782 imperfectly tagged. These significant
associations between tagged SNPs inNCF2 andSMG7 transcript
abundance demonstrate that genetic variants within NCF2
associated with SLE may have functional effects on expression
of the adjacent gene SMG7. SMG7 encodes a component of the
mRNA ‘decay body’, which mediates nonsense-mediated
mRNA decay (NMRD) (41). Disruptions to NMRD have been
implicated in auto-antibody development, in particular, to
lupus auto-antigen La (42). Furthermore, SMG7 levels have
been shown to correlate negatively with lupus anti-nuclear anti-
body titers (43), suggesting that SMG7 in particular and NMRD
in general may play a protective role against auto-antigen gener-
ation and SLE progression.
Molecular modeling of the novel coding variants
We modeled protein structural effects of non-synonymous
rs13306575 (R395W), which was independently associated
with SLE in HS and KR. The risk allele at rs13306575 results
in an R395W mutation in exon-14 of the p67phox protein
encoded by NCF2. A previous crystal structure of the PB1
domain complex of p40phox and p67phox (44) showed that R395
forms a salt bridge with the carbonyl oxygen of P339 in
p40phox and R395W may disrupt this salt bridge (Fig. 2A). Add-
itionally, the tryptophan side-chain introduces significant
clashes within the PB1 domain, likely destabilizing the domain
and its interactions.
Similarly, the risk allele at rs35937854 produces a V297A
substitution in exon-10 and is predicted to disrupt a highly con-
served binding site (ENCODE/HMR track) for the transcription-
al activator Myb (Myeloblastosis oncogene). Myb is critical for
hematopoiesis, particularly monocyte–macrophage differenti-
ation and proliferation (45). The V297A substitution in p67phox
is located in the first SH3 domain, which interacts with
gp91phox (46). This mutation is predicted to destabilize SH3
domain folding (Fig. 2B), which may in turn weaken the inter-
action with gp91phox. These observations suggest that
rs13306575 and rs35937854 risk alleles may have both direct
and indirect effects on protein function.
Luciferase reporter assay with the synonymous variant
Bioinformatic analysis demonstrated that the synonymous
variant rs17849501 (A202A) may act as a cis-regulatory
element to influence protein and mRNA expression. During
protein translation, the wild-type codon (GCG) pairs with the
least abundant alanine tRNA, whereas the complementary
tRNA for the mutant codon (GCA) is abundant (www.kazusa.
or.jp/codon), suggesting that the risk allele could increase trans-
lation efficiency. Moreover, rs17849501 is in a highly conserved
region annotated as active chromatin in GM12878 cells
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(ENCODE/Broad Histone track). This region is notably
enriched for trimethylated histone H3-Lys36 (H3K36Me3), a
transcriptional elongation signal, and trimethylated histone
H3-Lys27 (H3K27Me3), frequently associated with transcrip-
tional silencing. Furthermore, the cytosine in the rs17849501
wild-type allele is in a methylated CpG motif (ENCODE/
MeDIP-Seq track). Based on this evidence, we directly assessed
transcriptional activity of the rs17849501 locus with a luciferase
expression assay. The wild-type rs17849501 locus enhanced
transcription in MonoMac-6 cells by 15-fold over back-
ground. The rs17849501 locus carrying the risk allele boosted
expression by a further 40% (P ¼ 9.7 × 1028) (Fig. 3). Thus
the rs17849501 risk allele may increase transcriptional enhancer
activities by suppressing silencing function of the non-risk
allele, perhaps through epigenetic interactions. In combination
with potential increased translational efficacy, rs17849501
could dysregulate NADPHO even though the mutation does
not change protein sequence.
DISCUSSION
In the present study, we demonstrated that multiple independent
and robustly associated variants within the NCF2 gene, both
coding and non-coding, are predicted to influence SLE suscepti-
bility. Intriguingly, the set of SLE-associated SNPs was quite
different in each population.
This work also offers insight into possible mechanisms by
which SLE-associated variants in NCF2 may influence SLE
risk. First, associated SNPs have the potential to influence epi-
genetic regulation of this locus. For example, the synonymous
rs17849501 variant seems to disrupt an endogenous silencer
module. This SNP is in strong LD with rs17849502 and may con-
tribute to the latter’s SLE association. Secondly, several of the
SNPs identified here may control expression of the adjacent
SMG7 gene, which has also been implicated in SLE risk.
Thirdly, three of the independently associated variants are non-
synonymous mutations with the potential to disrupt protein
Figure 2. (A) Effect of rs13306575 (R395W) on the interactions between p67phox and p40phox. Structure (PBD# 1OEY) of p67phox-R395 (wild-type) (top) making an
ion pair with the carbonyl oxygen of P339 in p40phox; lost in R395W (mutant); the tryptophan side also introduces clashes (bottom). (B) Effect of rs35937854 (V297A)
on the conformation and stability of the first SH3 domain.
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function. For example, the novel amino acid mutation caused by
rs35937854 (V297A) likely destabilizes the first p67phox SH3
domain and presumably its binding interactions. Finally, in HS
two of the non-synonymous SNPs were polymorphic. Since mul-
tiple interacting loci may contribute to SLE susceptibility, we
assessed SNP–SNP interaction (epistasis) to better understand
NCF2 association with SLE. The SNPs that showed the strongest
interaction, rs17849502 and rs13306575, yield amino acid sub-
stitutions that are separated by just 6 positions in the PB1 domain
of p67phox. The rs17849502 mutation has been shown to adverse-
ly affect binding between the p67phox-PB1 domain and Vav1
(47), and the rs13306575 mutation likely affects binding of the
p67phox-PB1 domain to p40phox (44). Genetic interaction
between these variants suggests that destabilizing both of these
interactions may have a synergistic disruptive effect on the for-
mation and overall activity of the NADPHO complex.
Functional mutations in NADPHO genes that adversely affect
complex assembly have been shown to disrupt ROS production
and predispose patients to primary immunodeficiency, such as
chronic granulomatous disease (CGD) (48). Assembly of the
NADPHO complex requires precise coordination of several
protein subunits (49–51), and multiple mutations affecting the
expression and/or function of the various components of
NADPHO (CYBA, CYBB, NCF1, NCF2, NCF4) (52–62) are
strongly predisposing for CGD. In addition, rs13306575
(R395W), an SLE-associated SNP identified here, has been pre-
viously associated with inflammatory CGD (63,64), although
the rs13306575 mutation was paired with an in-frame deletion
of three amino acids in the N-terminal tetratricopeptide repeat
domain, which binds Rac-GTP (65). One GCD patient with the
R395W mutation had no detectable p67phox in her neutrophils
based on western blot (64). Several other inflammatory diseases
have also been associated with NADPHO genes, including in-
flammatory bowel disease with NCF2 (66), Crohn’s disease
with NCF4 (67,68) and rheumatoid arthritis with NCF2, NCF4
andRAC2 (69).A recent large-scale resequencing study demon-
strated that rs17849502/rs17849501 is also associated with
celiac disease (70). This indicates that NCF2 may be a
common autoimmunity gene, increasing susceptibility for mul-
tiple autoimmune/inflammatory phenotypes (70). Because
NADPHO is a central regulator of ROS levels, which are critical
for regulation of inflammation, adaptive immunity, intracellular
signaling, chemoattraction and autophagy (71–77), it is not sur-
prising that mutations affecting this complex are implicated in
inflammatory diseases.
Interestingly, recent reports demonstrated that physiological-
ly appropriate NADPHO function is crucial for the formation of
neutrophil extracellular traps (NETs) (78–80) and have linked
improper clearance of NET debris with auto-antigen production
in SLE (80–82). NETs are extracellular structures composed of
chromatin and granular proteins that are secreted by neutrophils
to entrap and kill microorganisms (83,84). Monocytes from SLE
patients have a reduced ability to degrade in vitro generated
NETs, and the abundance of NETs in SLE patients is correlated
with serum levels of immunogenic complexes (82). Further-
more, patients that failed to degrade NETs had more active
disease (85). Indeed, Campbell et al. (80) found that Nox2-
deficient (and thus NADPHO-deficient) mice had severe lupus,
including increased renal disease and elevated autoantibody pro-
files. These results suggest that failure to undergo normal
NADPHO-dependent cell death may increase immunogenic cel-
lular debris, breaking self-tolerance. TheNCF2 variants discov-
ered here could act through a similar mechanism, by disrupting
ROS production, leading to accumulated NET debris and auto-
antigenicity.
Our results suggest that NCF2 influences SLE risk through a
complex balance between many underlying predisposing var-
iants, some of which perturb expression and some of which
affect the structure and function of the translated protein. Inter-
actions with other genes would be expected to alter this balance,
causing SNPs to have discordant effects on SLE risk in different
populations when their intergenic interactions varied between
populations. The potentially functional SNPs identified here
have dramatically different effects on SLE risk in different popu-
lations, underscoring the importance of using large, multi-ethnic
studies not only in elucidating the underlying mechanisms of
SLE, but also in identifying predisposing variants explaining
additional phenotypic variance (i.e. missing heritability) of
complex diseases such as SLE. Our bioinformatics and function-
al work strongly suggests that these SNPs contribute directly to
disruption of NADPHO. However, it is possible that the
observed allelic heterogeneity results, at least in part, from un-
identified causal SNPs tagged by the SNPs associated in this
study. Further experiments may clarify this issue.
In summary, our strategy using a large, multi-ethnic case–
control SLE cohort for dense ImmunoChip-based fine-mapping
with imputation-based association analysis, followed by condi-
tional analysis, bioinformatics analysis and molecular modeling,
identified 6–7 (two behave dependently) potentially functional
variants in NCF2. For many of the variants, we have implicated
mechanisms by which they may impact NADPHO function.
Figure 3. Enhancer activity of exonic DNA sequences carrying the rs17849501
wild-type (501G) or risk allele (501A). The 106-mer DNA sequences carrying
rs17849501 non-risk (G) and risk (A) alleles were cloned into an enhancer/silen-
cer assay vector (TKmin-MGL.1, Xactagen, USA) for luciferase activity carry-
ing a minimal TKmin promoter. These clones were transiently transfected by
electroporation to MonoMac-6 cells, and luciferase activity was measured at
6 h after transfection (Klan and Steinhilber, 2003). Transfection efficiency was
more than .90% in all cases (measure of CMV promoter control, data not
shown). TKmin ¼ vector only, MCS ¼ vector with multiple cloning sites,
501G ¼ vector with wild-type allele, 501A ¼ vector with risk allele. Bars repre-
sent the average promoter activity and standard deviation for nine replicates,
expressed in relative luminescence units.
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However, no variant was associated in all four populations, and
some variants showed significant associations only within a
single population. This high degree of allelic heterogeneity in
NCF2 association with SLE suggests that several risk variants
may be undiscovered. In particular, given that rare variants
could not be successfully imputed, this study provides both the
groundwork and the impetus for full gene sequencing in multiple
ethnically diverse populations in a follow-up case–control
study. Thus, understanding how these SNPs contribute to SLE
can focus future functional experiments vital to uncovering
how genetic variability predisposes for disease pathogenesis.
MATERIALS AND METHODS
Study samples, genotyping and quality control
The study samples were recruited through the Lupus Family
Registry and Repository (86) at the Oklahoma Medical Research
Foundation (OMRF), the Cincinnati Children’s Hospital Medical
Center (CCHMC), the University of Texas SouthWestern
(UTSW), the Center for Genomics and Ontological Research,
Spain (GENYO) and the Hanyang University, South Korea
(HU). Protocols for this study were approved by the Institutional
Review Boards (IRBs) where participants were recruited
(OMRF, UTSW, CCHMC, GENYO and HU). Every individual,
including SLE cases and healthy controls, provided written
consent at enrollment. All SLE patients met a minimum of 4
out of 11 1997 American College of Rheumatology revised clas-
sification criteria for SLE (27,87). Controls were healthy indivi-
duals, who did not have lupus or any other autoimmune disease.
Most study controls were recruited through the Lupus Family
Registry and Repository (LFRR) (86). All controls were
recruited from the same countries and areas where patients
were recruited. Whenever possible, they were selected to have
the same self-reported ethnicity as the patient population. Con-
trols were recruited with IRB approval by participating physi-
cians, or were recruited from health fairs, community health
clinics, or area schools. Out of study GWAS controls were
obtained with permission through dbGaP.
SLE cases and healthy controls were genotyped on the Illu-
mina ImmunoChip array (28) (Supplementary Material,
Table S1). For quality control (QC), subjects were excluded
from analysis if they had .10% missing genotyping, were
related to any other study participant (.25% identical by
descent), or were population stratification outliers based on
PCA. SNPs were removed for .10% missing genotyping,
being out of Hardy–Weinberg equilibrium (PHWE , 0.001 in
controls), or for poor clustering.
We increased statistical power to detect lupus-associated var-
iants by incorporating out-of-study healthy controls obtained
through dbGaP (Supplementary Material, Table S1). For AA,
we added controls from the Health and Retirement Study
(HRS) genotyped on the Illumina OMNI 2.5 platform. For EA,
we incorporated control genotypes from the GENIE UK-ROI
Diabetic Nephropathy GWAS (GoKIND), Genes and Blood
Clotting Study (GABC) and NGRC Parkinson’s Disease Study
(CIDR) genotyped on the Illumina Omni1-Quad platform, and
HRS control samples genotyped on the Illumina OMNI 2.5 plat-
form. We also added data from HS SLE cases and controls gen-
otyped on the Illumina HumanOmni 1 platform for a separate
GWAS study (unpublished data). Genotypes were merged
with our data for further QC (described subsequently) to insure
high-quality imputation.
Population structure and sample quality control
In order to obtain a homogeneous sample, for EA we removed
individuals with ,90% European ancestry. For AA, we
removed individuals with ,25% African ancestry. All partici-
pants in this study were filtered by PCA to identify population
outliers as previously reported (88). Samples exceeding three
standard deviations along any statistically significant principal
component were defined as outliers and removed from the
study. For each population, we merged genotype data with unre-
lated HapMap reference population data. We selected LD
pruned variants (r2, 0.2) that had minor allele frequency
(MAF) .1% and that were separated by at least 500 kilobases
(kb). For PCA, we included 7170 SNPs for EA, 3501 SNPs for
AA, 3646 SNPs for HS and 6928 SNPs for KR (Supplementary
Material, Fig. S2). The number of SNPs chosen was a comprom-
ise between the size of the common data set and the number of
independent SNPs. Although the number of SNPs to estimate
population structure and ancestry proportions seems small, it is
comparable to the sets used in other studies (89–90).
We used GCTA software (35) to estimate the first ten principal
components for each ethnic population. All samples were plotted
by their estimated ancestry proportion relative to the three con-
tinental reference populations (Supplementary Material,
Fig. S3). We estimated the mean and standard deviation (SD)
for each ethnic population for the first three principal compo-
nents and removed samples that were outside three SD from
the mean at each tail of the distribution.
To test for differences across data sets and potential population
structure within each ethnic group, we selected variants from the
combined data set common between unrelated HapMap samples
(CEU, CHB + JPT and YRI) genotyped on the Illumina Human-
Omni 2.5 platform. We selected LD pruned variants that had an
MAF.1% and that were separated by at least 500 kb for estima-
tion of admixture proportions. Ancestry proportion was estimated
for all samples using ADMIXTURE (91) with 1–9 ancestry com-
ponents. The optimum number of ancestry components was deter-
mined using the Bayesian Information Criterion (BIC) and the
cross-validation error rate.
Imputation
Imputation is a statistical method used to probabilistically deter-
mine missing or untyped genotypes using a densely mapped ref-
erence panel. We performed imputation-based analysis in our
ethnic-specific case-control samples. Genotypes included 145
SNPs from the ImmunoChip, 55 SNPs from EA and AA
GWAS controls (34 overlapped between the platforms), and
19 SNPs from HS GWAS controls (all of which overlapped
with ImmunoChip SNPs). We used publicly available 1000
Genomes Project data (2010-11-23 1000G Phase I) as reference
panels for imputation, including 246 for AA (YRI + LWK +
ASW), 381 for EA (GBR + FIN + IBS + CEU + TSI), 181
for HS (PUR + CLM + MXL) and 286 for Asians (AS;
JPT + CHB + CHS). After QC 250 SNPs from the NCF2
region (Chr1: 183,523,470-183,573,858 bp) were available for
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analysis. Imputation was performed using MACH-ADMIX (31),
which provided an imputation quality metric (Rsq). To insure
high-quality imputation, only SNPs that passed post-imputation
QC (Rsq . 0.7,PHWE . 0.001 in controls, MAF. 0.5%) were
used for analysis.
Threshold for population-specific gene-wide significance
adjusting for multiple testing and LD
Since we used a dense set of SNPs within NCF2 to correct for
multiple testing in each population, we used the spectral decom-
position method implemented in SNPSpD (32,33). For each
population, the experiment-wide significance level (a ¼ 0.05)
was adjusted for multiple testing by estimating the effective
number of independent SNPs by spectral decomposition of the
pair-wise LD matrices adjusted with a Bonferroni correction.
Since LD structures were different between the four populations,
the effective numbers of independent SNPs (capturing most of
the information across the entireNCF2 gene) were also different
across populations.
Association analysis, population stratification adjustment
and conditional analysis
We performed single SNP association analysis in each population
to compare allele frequencies between cases and controls using
the x2 test (one degree of freedom), and calculated odds ratios
(OR) and 95% confidence intervals (95% CI) using the PLINK
(30) software package. In order to account for population struc-
ture, we used the first three principal components identified
through PCA (92) as covariates in a logistic regression model.
We also verified our results separately by adjusting three of the
four individual ancestry proportions estimated by ADMIXTURE
(93) as covariates. By using both types of stratification correction
alternatively, we ensured that we accounted for stratification.
We used several methods to identify SNPs with independent
effects in each ethnic population. First, we performed pair-wise
conditional analysis in a step-wise manner using WHAP (94).
Initially, we conditioned on the most significant SNP, then on
the next most significant SNP, and so on, for each SNP that
had passed the population-specific significance threshold in the
imputation-based analysis. At each step, SNPs that lost signifi-
cance after conditioning on the lead SNP were excluded from
subsequent analyses until all residual association within the
gene was accounted for. Secondly, we confirmed independent
association using haplotype analysis implemented in PLINK
(Supplementary Material, Table S5). Both omnibus and
haplotype-specific association tests were used to evaluate
these independent SNPs. An omnibus test was used to assess
all haplotypes combined for SLE-association. Once association
was observed with the omnibus test, a SNP-specific test as well
as haplotype-specific test were used to identify whether any spe-
cific SNP or haplotype containing risk allele(s) explaining the
omnibus association. Thirdly, we also verified independence
between SNPs by their LD (r2).
SNP–SNP interaction
For genetically complex diseases such as SLE, multiple interact-
ing loci may contribute to disease susceptibility. Therefore, we
assessed SNP–SNP interaction (epistasis) to better understand
NCF2 association with SLE. First, we examined SNP–SNP
interactions for independently associated SNPs within each
population using a logistic regression model implemented in
R. To account for population structure, we also adjusted for
either the first three principal components estimated by GCTA
or by major individual ancestry populations estimated by AD-
MIXTURE, described earlier. Significance of the relevant
model terms were evaluated by comparing the log-likelihood
difference between the null model (only independent effects)
and the full model (with SNP–SNP interaction) with a x2 distri-
bution with degrees of freedom (df) equal to the difference in the
numbers of unconstrained parameters between models. We
confirmed our results using the logistic regression model imple-
mented in FITF (36), a PLINK (30) two-locus test and with
GAIA (95).
Secondly, we verified our earlier results of potential SNP–
SNP interaction using non-parametric generalized multifactor
dimensionality reduction (GMDR) technique (96,97). A
10-fold cross-validation that randomly divides each data set
into 10 randomly selected independent data sets (nine training
sets and one testing set). This approach is the gold-standard in
data mining and minimizes the bias introduced (due to random
variation in the split or overestimation of the results) by aver-
aging results across many divisions of the data (Dr Jason
H. Moore, personal communication). The epistasis model (and
its prediction error) was estimated for each training set and
was then validated (98). The greatest cross-validation consist-
ency (CVC) and the highest prediction accuracy were selected
as the best predictor of this disease outcome. P-values were
determined by the sign test, a robust non-parametric test imple-
mented in the software.
Once we detected significant interaction between a pair of
SNPs, we then usedx2 test to assess the magnitude of association
between individuals with at least one risk allele at either inde-
pendently associated SNP, or at both independently associated
SNPs, compared with those with no risk alleles as a baseline.
ORs and P-values were used to assess the magnitude of the
effect size.
In silico expression analysis
We obtained data from GeneVar (37,38) (Array Express Acces-
sionE-MTAB-264,protocolA-MEXP-930) forEBV-transformed
lymphoblastoid cells from four HapMap populations (CEU ¼ 35,
CHB + JPT ¼ 80, YRI ¼ 38). Expression quantitative trait
locus (eQTL; Illumina Human WG-6) data were merged with
the corresponding genotypes at the independently associated
variants identified in this study. Association analysis for
cis-eQTLs in NCF2 (GI_4557786-S) and neighboring genes
SMG7 (GI_42476073-A and GI_42475557-I) and ARPC5
(GI_13569955-S and GI_23238212-S) were performed in
PLINK. To confirm these results, we used data from the
mRNA by SNP browser (39,40) to investigate whether any of
these SNPs were associated with changes in transcript abun-
dance. The mRNA by SNP browser data were obtained from
lymphoblastoid cells of 206 families of British descent (297
sibling pairs and 11 half-sibling pairs) using the Affymetrix
HG-U133 Plus 2.0 Chip (39,40). Association between SNPs
and expression probes in the mRNA browser was determined
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by regression analysis as described in Dixon et al. (40). We iden-
tified tagSNPs in linkage disequilibrium (r2 ≥ 0.2) with inde-
pendently associated SNPs in CEU, YRI and CHB + JPT
populations as a proxy for EA, AA and KR, respectively.
Luciferase reporter assay
We cloned exonic 106-mer sequence (bases 183,542,269-183,
542,375) containing risk or non-risk alleles of rs17849501 into
a luciferase assay vector, under a minimal thymidylate kinase
promoter (TKmin, Xactagen Inc., USA). MonoMac-6 cells
were transiently transfected in one of four groups: vector only,
vector carrying multiple cloning sites (MCS), risk allele carrying
DNA or non-risk allele carrying DNA sequences. Luciferase ex-
pression was measured at 6 h post-transfection as suggested
(99), using the Gaussia Luciferase Assay (GLOW) with a
Gaussia luciferase assay kit (Xactagen, LLC). Media was aspi-
rated from transfected cells, which were plated and washed
once. One hundred microliters of GLum.1 assay buffer (plus coe-
lenterazine substrate) and 50 ml of GLum.1 assay reagent were
added to each well and dark incubated for 5 min prior to
reading luminescence (SpectraMax L, Molecular Devices:
475 nm). Measurements (relative luminescence units) were nor-
malized to untransfected cells as controls. After normalization,
statistical significance was calculated using t-tests assuming
unequal variance.
Bioinformatics
All chromatin properties were examined using the UCSC
Genome Browser (http://genome.ucsc.edu), based on the
ENCODE annotations and other data contained in all ‘Regula-
tion’ tracks.
Protein modeling
Structure figures were generated using PyMOL (http://www.
pymol.org). The structure of the first SH3 domain (rs35937854/
V297A) was taken from PDB file 2DMO. The structure of the
PB1 domain (rs13306575/R395W and rs17849502/H389Q) was
taken from PDB file 1OEY (44).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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